Quantitative Xylazine Measurement Among Non-Fatal Opioid Overdose (OD) Patients in the Emergency Department (ED)
Xylazine, a veterinary medication and alpha-2 agonist drug with clinical effects including prolonged sedation and skin/soft tissue wounds, has been increasingly detected with fentanyl in the illicit opioid supply. Due to its rapid emergence, limited knowledge exists regarding xylazine's health effects. In this proposed research, Dr. Love will measure xylazine and its metabolites in blood and urine samples using laboratory and point-of-care assays. Working at two New York City emergency departments, Dr. Love will collect waste serum and urine from opioid overdose patients to measure xylazine and its metabolite concentrations. The researcher will also perform qualitative assessment of urine samples with xylazine test strips to characterize urine xylazine detection using a harm reduction tool.
Study Type
OBSERVATIONAL
Enrollment
15
NYC Health + Hospitals/Elmhurst
Elmhurst, New York, United States
RECRUITINGIcahn School of Medicine
New York, New York, United States
NOT_YET_RECRUITINGXylazine Concentration in Blood
Concentration of Xylazine in blood as determined by lab.
Time frame: 6 months
Xylazine Strip Specificity and Sensitivity
Measuring Xylazine test strip specificity and sensitivity using excess urine samples.
Time frame: 6 months
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.